Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

"ROADMAP" controversies.

Cohen DL, Townsend RR.

J Clin Hypertens (Greenwich). 2011 Aug;13(8):628. doi: 10.1111/j.1751-7176.2011.00487.x. Epub 2011 Jun 27. No abstract available.

2.

Diabetes: ROADMAP: the road to renoprotection?

Roscioni SS, Heerspink HJ, de Zeeuw D.

Nat Rev Nephrol. 2011 May 24;7(8):427-8. doi: 10.1038/nrneph.2011.71. No abstract available.

PMID:
21610679
3.

Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.

Ingelfinger JR.

N Engl J Med. 2011 Mar 10;364(10):970-1. doi: 10.1056/NEJMe1014147. No abstract available.

PMID:
21388316
4.

Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.

Ritz E, Menne J, Haller H.

Nephrol Dial Transplant. 2012 Dec;27 Suppl 4:iv28-30. doi: 10.1093/ndt/gfs424. No abstract available.

5.

Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?

Consuegra-Sánchez L, Sanchis J, Núñez J, Cascón JD, Villegas M, Picó F.

Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):378-80. doi: 10.1016/j.recesp.2011.05.024. Epub 2011 Aug 12. No abstract available.

PMID:
21840109
6.

Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.

Chatzikyrkou C, Menne J.

Expert Rev Cardiovasc Ther. 2012 Sep;10(9):1087-92. doi: 10.1586/erc.12.100. Review.

PMID:
23098143
7.

Olmesartan, microalbuminuria, and type 2 diabetes.

Yudkin JS, Lehman R.

N Engl J Med. 2011 Jun 9;364(23):2260; author reply 2262-3. doi: 10.1056/NEJMc1104826#SA1. No abstract available.

PMID:
21651401
8.

Olmesartan, microalbuminuria, and type 2 diabetes.

Lammert A, Krämer BK, Krüger B.

N Engl J Med. 2011 Jun 9;364(23):2261; author reply 2262-3. doi: 10.1056/NEJMc1104826#SA3. No abstract available.

PMID:
21651399
9.

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.

N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.

10.

[Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].

Halimi S.

Presse Med. 2005 Oct 22;34(18):1300-2. Review. French.

PMID:
16269993
11.

Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study.

Padwal R, Lin M, Etminan M, Eurich DT.

Hypertension. 2014 May;63(5):977-83. doi: 10.1161/HYPERTENSIONAHA.113.02855. Epub 2014 Feb 17.

12.

Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.

Walker AM, Liang C, Clifford CR, Parker C, Feldman A.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):348-56. doi: 10.1002/pds.3558. Epub 2013 Dec 23.

PMID:
24375940
14.

Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?

Ruilope L, Izzo J, Haller H, Waeber B, Oparil S, Weber M, Bakris G, Sowers J.

J Clin Hypertens (Greenwich). 2010 Jun;12(6):422-30. doi: 10.1111/j.1751-7176.2010.00289.x. Review.

15.

Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.

Catalá-López F, Martín-Serrano G, Maciá MA, Montero D.

Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):678-9; author reply 679-80. doi: 10.1016/j.recesp.2012.03.006. Epub 2012 May 17. English, Spanish. No abstract available.

PMID:
22608016
16.

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ.

Eur Heart J. 2011 Jun;32(12):1493-9. doi: 10.1093/eurheartj/ehr017. Epub 2011 Mar 18.

17.

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A.

J Hypertens. 2006 Feb;24(2):403-8.

PMID:
16508590
18.

[Therapy of hypertension. A new rapidly effective AT1 blocker].

[No authors listed]

MMW Fortschr Med. 2002 Jun 20;144(25):55. German. No abstract available.

PMID:
12136675
19.

The challenges of comparing results between placebo controlled randomized trials and non-experimental new user, active comparator cohort studies: the example of olmesartan.

Camelo Castillo W, Delaney JA, Stürmer T.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):357-60. doi: 10.1002/pds.3602. Epub 2014 Mar 3. No abstract available.

20.

Olmesartan, microalbuminuria, and type 2 diabetes.

Fioretto P, Mauer M.

N Engl J Med. 2011 Jun 9;364(23):2260-1; author reply 2262-3. doi: 10.1056/NEJMc1104826#SA2. No abstract available.

PMID:
21651400
Items per page

Supplemental Content

Write to the Help Desk